Meloxicam Tablet
Product Images NDC 72789-447

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 72789-447). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (72789446)

MELOXICAM USP 7.5 mg oral tablet package label from PD-Rx Pharmaceuticals, Inc. The label shows a package containing 14 tablets. It includes the NDC number 72789-446-14, lot number J24Z99, and expiration date 06/2027. The label cautions to keep out of reach of children and advises not to consume alcohol while taking the medication.*

FDA Label Image

Image (72789447)

MELOXICAM USP 15 MG oral tablet label showing 15 tablets per bottle, labeled by PD-Rx Pharmaceuticals, Inc. It includes dosage and storage warnings, with instructions to take with food. The label displays NDC 72789-447-15, lot number J24Z98, and expiration date 06/2027, along with a barcode and regulatory information.*

FDA Label Image

Mg1 (Mg1)

A text panel providing warnings related to NSAID use, specifically advising against NSAID use before or after coronary artery bypass graft surgery and cautioning about increased risk of heart attack when NSAIDs are taken after a recent heart attack unless directed by a healthcare provider.*

FDA Label Image

Mg2 (Mg2)

A text panel excerpt discussing increased risk factors for ulcers or bleeding with NSAID use, listing conditions such as previous ulcers, use of corticosteroids or anticoagulants, older age, longer NSAID use, smoking, alcohol consumption, poor health, advanced liver disease, and bleeding problems.*

FDA Label Image

Mg3 (Mg3)

A text panel providing detailed medication information, including usage instructions, precautions, warnings, and side effects for the drug Meloxicam tablets. The content outlines patient guidance on dosage, potential allergic reactions, interactions with alcohol and other drugs, and advice on when to seek medical attention.*

FDA Label Image

Mg4 (Mg4)

A text panel listing warnings related to serious side effects, including signs of stroke, heart attack, and allergic reactions. The list includes symptoms such as sudden numbness, chest pain, slurred speech, and swelling of the face or throat.*

FDA Label Image

Mg5 (Mg5)

A partial text panel from a Meloxicam tablet label, listing various potential side effects including nausea, weakness, diarrhea, itching, yellowing of skin or eyes, stomach pain, flu-like symptoms, vomiting blood, blood in bowel movements, unusual weight gain, skin rash with fever, and swelling of extremities. The text is presented as bulleted points.*

FDA Label Image

Structural (Structural Formula)

Chemical structure of Meloxicam, showing its molecular arrangement including a thiazole ring, sulfonamide group, and ketone functionalities.*

FDA Label Image

Table 1a (Table 1a)

A data table presenting the percentage of adverse events occurring in 2% or more of Meloxicam patients in a 12-week osteoarthritis placebo- and active-controlled trial. It compares adverse events across four groups: Placebo, Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, and Diclofenac 100 mg daily, categorized by gastrointestinal, body as a whole, central and peripheral nervous system, respiratory, and skin events.*

FDA Label Image

Table 1b (Table 1b)

A data table presenting adverse events occurring in 2% or more of patients treated with Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, or placebo in two 12-week rheumatoid arthritis placebo-controlled trials. It compares the percentage of patients experiencing various gastrointestinal, general disorders, infections, musculoskeletal, nervous system, and skin-related adverse events across treatment groups.*

FDA Label Image

Table 2.1 (Table 2.1)

A data table listing adverse reactions organized by body systems including Body as a Whole, Cardiovascular, Central and Peripheral Nervous System, Gastrointestinal, Heart Rate and Rhythm, Hematologic, Liver and Biliary System, Metabolic and Nutritional, Psychiatric, Respiratory, Skin and Appendages, Special Senses, and Urinary System. Each section details various side effects such as allergic reactions, cardiac issues, gastrointestinal ulcers, psychiatric symptoms, and renal failure.*

FDA Label Image

Table 2 (Table 2)

Data table presenting adverse events occurring in 2% or more of patients treated with Meloxicam 7.5 mg or 15 mg daily in 4 to 6 weeks and 6 month controlled osteoarthritis clinical trials. The table includes gastrointestinal, body, nervous system, hematologic, musculoskeletal, psychiatric, respiratory, skin, and urinary system events with percentage occurrences for each Meloxicam dosage and duration group.*

FDA Label Image

Table 3.1 (Table 3.1)

A drug interaction information panel discussing the clinical impact and intervention recommendations for meloxicam use with lithium, methotrexate, cyclosporine, NSAIDs and salicylates, and pemetrexed. The text includes monitoring advice and cautions for these drug combinations.*

FDA Label Image

Table 3 (Table 3)

A table titled 'Clinically Significant Drug Interactions with Meloxicam' detailing interactions with drugs affecting hemostasis, aspirin, ACE inhibitors, angiotensin receptor blockers, beta-blockers, and diuretics. It includes sections on clinical impact and intervention recommendations for each drug category related to meloxicam use.*

FDA Label Image

Image Description (Table 4)

A pharmacokinetic data table showing single dose and steady-state parameters for oral 7.5 mg and 15 mg Meloxicam tablets and capsules. It includes values for healthy adults, elderly males and females, and patients with renal or hepatic insufficiency under fasted conditions, presenting metrics like Cmax, tmax, half-life, clearance, and volume of distribution with variability percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.